In a monumental advancement in the field of cancer research, scientists and doctors at Mumbai’s esteemed Tata Institute have unveiled a tablet that could revolutionize cancer treatment. Priced at a mere Rs 100, the newly developed tablet, named ‘R+Cu’, aims to effectively prevent the recurrence of cancer in patients while significantly reducing the side effects of aggressive treatments like radiation and chemotherapy.
The development of ‘R+Cu’ comes after extensive research and testing conducted at Tata Institute, renowned for its pioneering work in cancer research and treatment. Dr. Rajendra Badve, a senior cancer surgeon at Tata Memorial Hospital, explained the science behind the tablet’s efficacy. He noted that during their research, human cancer cells were introduced into rats, leading to the formation of tumors. Subsequent treatment with radiation therapy, chemotherapy, and surgery revealed a crucial discovery: dying cancer cells release tiny particles known as cell-free chromatin particles (cfChPs). These particles have the potential to transform healthy cells into cancerous ones, facilitating the spread of cancer in the body.
To combat this phenomenon, the researchers developed the ‘R+Cu’ tablet, which contains pro-oxidant ingredients including resveratrol and copper. When ingested orally, the tablet triggers the production of oxygen radicals in the stomach. These radicals then swiftly enter the bloodstream, targeting and destroying the harmful cfChPs circulating in the body. This groundbreaking mechanism effectively halts the spread of cancer cells, known as metastases, thereby reducing the risk of cancer recurrence.
The benefits of ‘R+Cu’ extend beyond its ability to prevent cancer recurrence. Researchers assert that the tablet also offers significant protection against the toxic side effects commonly associated with chemotherapy. During their presentation, the researchers hailed the tablet’s effects as the “Magic of R+Cu,” emphasizing its potential to transform cancer treatment.
The impact of ‘R+Cu’ is substantial, with a reported 50 percent reduction in the side effects of cancer treatment. Additionally, the tablet boasts a 30 percent effectiveness in preventing cancer from returning, offering hope to patients battling various forms of cancer, including those affecting the pancreas, lungs, and oral cavity.
Currently awaiting approval from the Food Safety and Standards Authority of India (FSSAI), the ‘R+Cu’ tablet is expected to be available in the market from June-July at an affordable price of Rs 100. This development marks a significant milestone in cancer treatment, potentially improving outcomes and quality of life for countless individuals affected by this challenging disease.
